# Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

> **NCT06136897** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Malignant Solid Neoplasm

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Echocardiography Test
- **BIOLOGICAL:** Pertuzumab
- **PROCEDURE:** Radiologic Examination
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT06136897
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-23
- **Primary completion:** 2021-11-03
- **Final completion:** 2027-01-15
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06136897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06136897, "Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06136897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*